Global Hallucination and Delusion Treatment Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Hallucination and Delusion Treatment Drugs market size was valued at US$ 8376 million in 2024 and is forecast to a readjusted size of USD 11140 million by 2031 with a CAGR of 4.2% during review period.

Hallucinations are sensory experiences which occur without an actual stimulus. Delusions are meant to be the strong beliefs which are false and donot exist and are secret in the mind of the person having the delusion. The treatment used for treating schizophrenia controls the behavior of patients. These medications control the dopamine in the brain, and therefore the overall behaviour of the schizophrenic patient.

The emergence of bipolar therapy is an important factor for the market growth. There are no direct medicines available to treat the disease. Factors such as loss of interest in life, restless thoughts, and abnormal mood are some of the main symptoms of the disease. These disorders are similar to treatments for hallucinations and delusions. Wide availability of multiple drugs is stimulating more demand in the market.

This report is a detailed and comprehensive analysis for global Hallucination and Delusion Treatment Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Hallucination and Delusion Treatment Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Hallucination and Delusion Treatment Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Hallucination and Delusion Treatment Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Hallucination and Delusion Treatment Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Hallucination and Delusion Treatment Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Hallucination and Delusion Treatment Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc, AstraZeneca, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd, Endo International plc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan NV, Sanofi, F. Hoffmann-La Roche Ltd, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Hallucination and Delusion Treatment Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Oral

Injectable

Market segment by Application

Hallucinations

Delusions

Major players covered

Pfizer Inc

AstraZeneca

Bristol-Myers Squibb Company

Dr. Reddy's Laboratories Ltd

Endo International plc

Teva Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd

Mylan NV

Sanofi

F. Hoffmann-La Roche Ltd

Bausch Health Companies Inc

Novartis AG

Lupin

Cipla Inc

Acadia Pharmaceuticals Inc

Bayer AG

Merck & Co., Inc

Johnson & Johnson Private Limited

H. Lundbeck A/S

Cardinal Health

Autism Speaks Inc

Mallinckrodt

Boehringer Ingelheim International GmbH

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Hallucination and Delusion Treatment Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Hallucination and Delusion Treatment Drugs, with price, sales quantity, revenue, and global market share of Hallucination and Delusion Treatment Drugs from 2020 to 2025.

Chapter 3, the Hallucination and Delusion Treatment Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Hallucination and Delusion Treatment Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Hallucination and Delusion Treatment Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Hallucination and Delusion Treatment Drugs.

Chapter 14 and 15, to describe Hallucination and Delusion Treatment Drugs sales channel, distributors, customers, research findings and conclusion.